ATF6-mediated unfolded protein response

Across TCGA cell cohorts, RNA activity of the ATF6-mediated unfolded protein response pathway is significantly associated with the drug response of multiple features, with the BLOOD_Leukemia cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Doxorubicin, Bortezomib, and Vismodegib, each associated with the pathway in up to 3 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Doxorubicin grouped by ATF6-mediated unfolded protein response-low versus -high activity in BLOOD_Leukemia.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Leukemia	Doxorubicin →	+0.613	+0.180	.011	.020	3	2
PANCREAS	Bortezomib →	+0.783	+0.536	<.001	.039	2	3
BLOOD_Leukemia	Vismodegib →	+0.185	+0.214	.011	.036	2	2
BLOOD_Leukemia	N24798-49-A1 →	+0.373	+0.179	.021	.046	3	1
BLOOD_Leukemia	UNC1215 →	+0.243	+0.171	.011	.033	3	1
BLOOD_Leukemia	BAY-MPS1 →	+0.767	+0.165	.010	.013	2	2

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Doxorubicin by ATF6-mediated unfolded protein response activity — BLOOD_Leukemia

Explore this box plot interactively →